Comparative Evaluation of Treatment of Oral Submucous Fibrosis with Intralesional Injections of Dexamethasone and Hyaluronidase with Triamcinolone Acetonide and Hyaluronidase

2015 ◽  
Vol 03 (03) ◽  
pp. 32-34
Author(s):  
TL Patel ◽  
◽  
Surjeet Singh
Keyword(s):  
Triamcinolone Acetonide ◽  
Comparative Evaluation ◽  
Oral Submucous Fibrosis ◽  
Intralesional Injections ◽  
Submucous Fibrosis

scholarly journals Comparative Study of Intralesional Dexamethasone Plus Hyaluronidase & Oral Colchicine in Patients with Oral Submucous Fibrosis

2018 ◽  
Vol 14 (2) ◽  
pp. 60-65
Author(s):  
Ganesh Prasad Neupane ◽  
Maya Rai ◽  
R. S. Rathore ◽  
V. K. Bhargava ◽  
A. K. Mahat ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Oral Mucosa ◽  
Oral Submucous Fibrosis ◽  
Mouth Opening ◽  
Study Groups ◽  
T Test ◽  
Significant Difference ◽  
Intralesional Injections ◽  
Submucous Fibrosis ◽  
Larger Sample

Introduction: Oral Submucous Fibrosis (OSMF) is a precancerous condition of the oral mucosa. It is characterized by excessive production of collagen leading to inelasticity of the oral mucosa and atrophic changes of the epithelium.Aim and objective: To evaluate the efficacy of oral Colchicine in comparison to intralesional injections of Dexamethasone plus Hyaluronidase in the management of OSMF patients.Materials and Methods: Fourty patients with OSMF were randomly divided equally into two groups. 20 patients in Dexamethasone group received biweekly intralesional injections of Dexamethasone (4mg/ml) plus Hyaluronidase 1500 IU in buccal mucosa for a period of 12 weeks. Other 20 patients in Colchicine group received oral Colchicine 0.5 mg tablets twice daily for 12 weeks. Parameters taken in the study were burning sensation, and mouth opening. Descriptive statistics, paired t test and unpaired t test were used for statistical analysis.Results and Conclusions: The pre- and post-treatment differences were found to be statistically significant for both the groups (p<0.001) and for both the treatment outcomes. When the average difference of the treatment outcomes was compared between the two study groups, statistically highly significant difference was noted (p <0.001) only in mouth opening but not in burning sensation.These encouraging results should prompt further clinical trials with Colchicine on a larger sample size to broaden the therapeutic usefulness of the drug in the management of OSMF. JNGMC,  Vol. 14 No. 2 December 2016, Page: 60-65

Study On Outcome of Different Combination of Dexamethasone, Hyaluronidase and Placental Extract for Treatment of Oral Submucous Fibrosis

KYAMC Journal ◽  
2019 ◽  
Vol 10 (2) ◽  
pp. 77-80
Author(s):  
Md Habibul Hasan ◽  
Md Shahidul Islam ◽  
Manjur E Mahmud ◽  
Ismat Ara Haider ◽  
Fatema Begum
Keyword(s):  
Oral Mucosa ◽  
Buccal Mucosa ◽  
Oral Submucous Fibrosis ◽  
Mouth Opening ◽  
T Test ◽  
Group I ◽  
Wide Range ◽  
Intralesional Injections ◽  
Submucous Fibrosis ◽  
Placental Extract

Background: Oral submucous fibrosis is a chronic debilitating disease of the oral cavity characterized by inflammation and progressive fibrosis of the submucosal tissues. It is a precancerous condition of the oral mucosa characterized by excessive production of collagen leading to inelasticity of the oral mucosa and atrophic changes of the epithelium. A wide range of treatment including drug management, surgical therapy, and physiotherapy have been attempted till date, with varying degrees of benefit, but none have been able to cure this disease. Objectives: To evaluate the efficacy of Intralesional 'Dexamethasone Plus Hyaluronidase plus Placental extract in comparison to intralesional injections of 'Dexamethasone plus Hyaluronidase in the management of OSMF patients. Materials and Methods: Thirty patients with OSMF were randomly divided equally into two groups. Fifteen patients in 'Dexamethasone plus Hyaluronidase(Group-I)' group received biweekly intralesional injections of Dexamethasone (4mg/ml) plus Hyaluronidase 1500 IU in buccal mucosa for a period of 12 weeks. Other Fifteen patients in'Dexamethasone plus Hyaluronidase plus placental extract (Group-II)' group received biweekly intralesional injections of Dexamethasone (4mg/ml) plus Hyaluronidase 1500 IU plus placental extract in buccal mucosa for a period of 12 weeks. Parameters taken in the study were burning sensation, and mouth opening. Descriptive statistics, paired t test and unpaired t test were used for statistical analysis. Results: The pre- and post-treatment Differences were found to be statistically not significant for both the groups (p<0.001) and for both the treatment outcomes. Conclusion: In the present study, the efficacy of Intralesional 'Dexamethasone Plus Hyaluronidase plus Placental extract' showed no superiority over intralesional injections of 'Dexamethasone plus Hyaluronidase' in the management of OSMF patients. KYAMC Journal Vol. 10, No.-2, July 2019, Page 77-80

Sign in / Sign up

Export Citation Format

Share Document